查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1908263

头颈癌治疗市场规模、份额和趋势分析报告：按治疗方法、给药途径、分销管道、地区和细分市场预测（2026-2033 年）

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

头颈癌治疗市场概览

2025年全球头颈癌治疗市场规模估计为25.3亿美元，预计2033年将达到62.5亿美元。

预计从 2026 年到 2033 年，该市场将以 12.00% 的复合年增长率成长。这一市场成长归因于头颈癌发病率的上升、对标靶治疗治疗和免疫治疗方法的需求增加以及诊断准确性的提高。

头颈癌的发生率持续上升，推动了对标靶治疗治疗和免疫疗法的需求不断增长。在不断涌现的临床证据的支持下，诊断准确性正在迅速提高。例如，2025年6月，GORTEC的III期REACH研究报告称， Avelumab联合治疗放射线治疗合格Cisplatin治疗的头颈癌患者取得了良好的疗效。该研究达到了其主要终点—改善无恶化生存期，并在500多名受试者中证实了良好的安全性。病患和医护人员对头颈癌的认识不断提高，也促进了早期发现，并扩大了多重药物合併治疗策略的应用。同时，人们越来越倾向于微创和低毒性的治疗方法，这推动了创新药物的普及。此外，扩大临床试验规模和加快监管核准流程也提高了产品在全球主要市场的可近性。

人类乳突病毒 (HPV) 相关口咽癌发生率的不断上升已成为市场成长的关键驱动因素。这些 HPV 相关亚型对治疗的反应往往各不相同，促使人们加大研发投入，并开发个人化治疗方案。临床指引越来越多地根据 HPV 感染状态来区分治疗方法，从而推动了精准医疗的需求。製药公司正在投资研发以病毒致癌机制为核心的治疗通讯协定，以扩大治疗范围。年轻成人 HPV 阳性病例的增加正在改变疾病的年龄分布，并创造新的市场机会。公众意识的提高和 HPV 相关恶性肿瘤筛检，有助于早期诊断和治疗。

在头颈癌治疗领域，联合治疗策略的应用日益普及，可望提高缓解率和存活率。将免疫疗法与化疗或标靶药物结合的治疗方法正在第一线治疗和难治性病例中进行测试。例如，FDA于2025年6月核准Keytruda用于PD-L1阳性头颈癌患者，这标誌着生物标记指导治疗日益受到关注。此核准也凸显了PD-L1阴性患者未被满足的医疗需求。 CEL-SCI公司的Multikine旨在填补这一空白，无论PD-L1状态如何，均可在标准治疗前对患者进行治疗。 Multikine旨在刺激早期免疫反应，是一种有望扩大治疗范围并改善不同患者群体预后的创新疗法。

目录

第一章调查方法和范围

第二章执行摘要

第三章 头颈癌治疗市场变数、趋势与范围

  • 市场谱系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 头颈癌治疗市场：依治疗方法和业务分析

  • 按治疗方法的市场份额（2025 年和 2033 年）
  • 按治疗方法分類的市场规模、预测和趋势分析（2021-2033 年）
  • 化疗
  • 免疫疗法
  • 标靶治疗

5. 依给药途径和业务分析分類的头颈癌治疗市场

  • 按给药途径分類的市场份额（2025 年和 2033 年）
  • 按给药途径分類的市场规模、预测和趋势分析（2021-2033 年）
  • 注射
  • 口服

6. 按通路和业务分析分類的头颈癌治疗市场

  • 按分销管道分類的市场份额（2025 年和 2033 年）
  • 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 零售药房和专科药房
  • 医院药房
  • 网路药房

第七章 头颈癌治疗市场：区域、估算与趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 市场规模及预测趋势分析，2021-2033年
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Eli Lilly and Company
    • Sanofi
    • Merck & Co., Inc.
    • Cumberland Pharmaceuticals Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd.
Product Code: GVR-2-68038-125-2

Head And Neck Cancer Therapeutics Market Summary

The global head and neck cancer therapeutics market size was estimated at USD 2.53 billion in 2025 and is projected to reach USD 6.25 billion by 2033, growing at a CAGR of 12.00% from 2026 to 2033. The market is growing due to the rising incidence of head and neck cancers, increasing demand for targeted and immunotherapy-based treatments, and advancements in diagnostic precision.

The incidence of head and neck cancers continues to rise, driving greater demand for targeted therapies and immunotherapy-based treatment approaches. Diagnostic accuracy is improving rapidly, supported by new clinical evidence. For instance, in June 2025, GORTEC's Phase III REACH trial reported positive outcomes for avelumab combined with radiotherapy in cisplatin-ineligible head and neck cancer patients. The study achieved its primary endpoint of improved progression-free survival and showed a favorable safety profile in more than 500 participants. Increasing awareness among patients and healthcare providers is also strengthening early detection and expanding the use of multi-line treatment strategies. Meanwhile, the growing preference for minimally invasive, lower-toxicity options is boosting the adoption of innovative drug classes. In addition, ongoing clinical trial expansion and accelerated regulatory pathways are improving product accessibility across major global markets.

The growing prevalence of human papillomavirus (HPV)-associated oropharyngeal cancers is emerging as a significant driver for market growth. These HPV-related subtypes often respond differently to treatment, prompting a rise in research and tailored drug development. Clinical guidelines increasingly differentiate therapeutic approaches based on HPV status, fueling demand for precision therapies. Pharmaceutical companies are investing in treatment protocols that address viral oncogenesis, expanding the therapeutic landscape. The increasing incidence of HPV-positive cases among younger adults has shifted the disease demographic, creating new market opportunities. Enhanced public awareness and screening for HPV-related malignancies contribute to earlier diagnosis and treatment initiation.

Adopting combination therapy strategies is gaining momentum in the head and neck cancer therapeutics space, offering improved response rates and survival outcomes. Treatment regimens integrating immunotherapy with chemotherapy or targeted agents are being tested in both first-line and refractory settings. For instance, in June 2025, the FDA's approval of Keytruda for PD-L1-positive head and neck cancer patients highlights the growing focus on biomarker-based therapies. The announcement also emphasized the unmet need in PD-L1-negative patients. CEL-SCI's Multikine aims to address this gap by treating patients before standard therapies, regardless of PD-L1 status. Designed to stimulate an early immune response, Multikine represents a novel approach that could broaden treatment access and improve outcomes across diverse patient groups.

Global Head And Neck Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global head and neck cancer therapeutics market report based on therapy, route of administration, distribution channel, and region:

  • Therapy Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Injectable
  • Oral
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail and Specialty Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Head and Neck Cancer Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Head and Neck Cancer Therapeutics Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2025 & 2033
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2021 to 2033 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Immunotherapy Market, 2021 - 2033 (USD Million)
  • 4.6. Targeted Therapy
    • 4.6.1. Targeted Therapy Market, 2021 - 2033 (USD Million)

Chapter 5. Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2025 & 2033
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable Market, 2021 - 2033 (USD Million)
  • 5.5. Oral
    • 5.5.1. Oral Market, 2021 - 2033 (USD Million)

Chapter 6. Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2025 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Retail and Specialty Pharmacies
    • 6.4.1. Retail and Specialty Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Hospital Pharmacies
    • 6.5.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 7. Head and Neck Cancer Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Eli Lilly and Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Therapy Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Sanofi
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Therapy Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck & Co., Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Therapy Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Cumberland Pharmaceuticals Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Therapy Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Bristol-Myers Squibb Company
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Therapy Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. AstraZeneca
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Therapy Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Takeda Pharmaceutical Company Limited
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Therapy Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Therapy Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. F. Hoffmann-La Roche Ltd.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Therapy Benchmarking
      • 8.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global head and neck cancer therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 5 Global head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 6 Global head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 9 North America head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 10 North America head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 12 U.S. head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 13 U.S. head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 15 Canada head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 16 Canada head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 18 Mexico head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 19 Mexico head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 22 Europe head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 23 Europe head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 25 UK head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 26 UK head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 28 Germany head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 29 Germany head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 31 France head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 32 France head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 34 Italy head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 35 Italy head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 37 Spain head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 38 Spain head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 40 Norway head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 41 Norway head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 43 Denmark head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 44 Denmark head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 46 Sweden head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 47 Sweden head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD
  • Table 50 Asia Pacific head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 53 Japan head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 54 Japan head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 56 China head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 57 China head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 59 India head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 60 India head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 62 Australia head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 63 Australia head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 65 South Korea head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 66 South Korea head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 68 Thailand head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 69 Thailand head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 72 Latin America head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 73 Latin America head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 75 Brazil head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 76 Brazil head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 78 Argentina head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 79 Argentina head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa head and neck cancer therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 85 South Africa head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 86 South Africa head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 91 UAE head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 92 UAE head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait head and neck cancer therapeutics market, by therapy, 2021 - 2033 (USD Million)
  • Table 94 Kuwait head and neck cancer therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 95 Kuwait head and neck cancer therapeutics market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Head and neck cancer therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Head and neck cancer therapeutics market dynamics
  • Fig. 12 Head and neck cancer therapeutics market: Porter's five forces analysis
  • Fig. 13 Head and neck cancer therapeutics market: PESTLE analysis
  • Fig. 14 Therapy market, 2021 - 2033 (USD Million)
  • Fig. 15 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Immunotherapy market, 2021 - 2033 (USD Million)
  • Fig. 17 Targeted therapy market, 2021 - 2033 (USD Million)
  • Fig. 18 Route of administration market, 2021 - 2033 (USD Million)
  • Fig. 19 Injectable market, 2021 - 2033 (USD Million)
  • Fig. 20 Oral market, 2021 - 2033 (USD Million)
  • Fig. 21 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 22 Retail and Specialty Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 24 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 25 Head and neck cancer therapeutics market revenue, by region
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 North America Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. country dynamics
  • Fig. 29 U.S. Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 30 Canada country dynamics
  • Fig. 31 Canada Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 32 Mexico country dynamics
  • Fig. 33 Mexico Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 34 Europe Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 35 UK country dynamics
  • Fig. 36 UK Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 Germany country dynamics
  • Fig. 38 Germany Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 France country dynamics
  • Fig. 40 France Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Italy country dynamics
  • Fig. 42 Italy Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Spain country dynamics
  • Fig. 44 Spain Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Norway country dynamics
  • Fig. 46 Norway Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden country dynamics
  • Fig. 48 Sweden Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 49 Denmark country dynamics
  • Fig. 50 Denmark Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 51 Asia Pacific Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Japan country dynamics
  • Fig. 53 Japan Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 China country dynamics
  • Fig. 55 China Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 India country dynamics
  • Fig. 57 India Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Australia country dynamics
  • Fig. 59 Australia Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 South Korea country dynamics
  • Fig. 61 South Korea Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 Thailand country dynamics
  • Fig. 63 Thailand Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 64 Latin America Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 MEA Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 South Africa country dynamics
  • Fig. 71 South Africa Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 Saudi Arabia country dynamics
  • Fig. 73 Saudi Arabia Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 UAE country dynamics
  • Fig. 75 UAE Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Kuwait country dynamics
  • Fig. 77 Kuwait Head and neck cancer therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 Company categorization
  • Fig. 79 Company market position analysis
  • Fig. 80 Strategic framework